A director at Bonesupport Holding AB bought 1,200 shares at 189.900SEK and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...
A director at Arjo AB bought 1,395,544 shares at 30.000SEK and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...
Coloplast A/S - Indkaldelse til ordinær generalforsamling 2025 Indkaldelse til ordinær generalforsamling 2025 Den ordinære generalforsamling i Coloplast A/S afholdes torsdag den 4. december 2025 kl. 15:30 på Coloplast A/S’ adresse, Holtedam 3 (Aage Louis-Hansen Auditorium), Humlebæk, Danmark. Indkaldelsen til den ordinære generalforsamling er vedlagt. For yderligere information, kontakt venligst Investorer og analytikereAnders Lonning-SkovgaardExecutive Vice President, CFOTlf. 4911 1111 Kristine Husted MunkSr. Director, Investor RelationsTlf. 4911 1800 / 4911 3266Email: Simo...
Coloplast A/S - Notice of Annual General Meeting 2025 Notice of Annual General Meeting 2025 The Annual General Meeting of Coloplast A/S will be held on Thursday, 4 December 2025 at 3:30 pm CET at the premises of Coloplast A/S, Holtedam 3 in Humlebæk (the Aage Louis-Hansen Auditorium), Humlebæk, Denmark. The notice of the Annual General Meeting is enclosed. For further information, please contact Investors and analystsAnders Lonning-SkovgaardExecutive Vice President, CFOTel. Kristine Husted MunkSr. Director, Investor RelationsTel. / Email: Simone Dyrby HelvindSr. Manager, Inve...
A director at Ambu AS bought 10,500 shares at 82.900DKK and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showi...
Coloplast A/S - Annual Report 2024/25 & Remuneration Report 2024/25 Coloplast A/S - Annual Report 2024/25 & Remuneration Report 2024/25 FY 2024/25 organic growth of 7% and EBIT margin1 of 28%. Reported revenue in DKK grew 3% to DKK 27,874 million.• Organic growth rates by business area: Ostomy Care 6%, Continence Care 8%, Voice & Respiratory Care 9%, Wound & Tissue Repair 8% and Interventional Urology 2%.• EBIT1,2 was DKK 7,670 million, a 5% increase from last year. The EBIT margin1,2 was 28%, against 27% last year.• Adjusted3 net profit before special items was DKK 5,148 million, a DKK 12...
Coloplast A/S - Årsregnskabsmeddelelse 2024/25 2024/25Årsregnskabsmeddelelse 1. oktober 2024 - 30. september 2025 Organisk vækst på 7% og en overskudsgrad1 på 28% i 4. kvartal. Den rapporterede omsætning i danske kroner steg 0%, negativt påvirket af valutaudviklingen samt frasalget af hudplejeforretningen.• Organisk vækst pr. område: Stomi 7%, Kontinens 9%, Stemme og Respiratorisk Pleje 9%, Wound & Tissue Repair 5% og Urologi 2%.• Væksten i Stomi var bredt funderet, med et godt bidrag fra nylige produktlanceringer og drevet af Europa og Øvrige markeder ex. Kina. Salget i Kina fa...
Coloplast A/S - Full-Year Financial Results 2024/25 2024/25Full year financial results 1 October 2024 - 30 September 2025 Coloplast delivered Q4 organic growth of 7% and an EBIT margin1 of 28%. Reported revenue in DKK grew 0% with negative impact from currencies and the Skin Care divestment.• Organic growth rates by business area: Ostomy Care 7%, Continence Care 9%, Voice & Respiratory Care 9%, Wound & Tissue Repair 5% and Interventional Urology 2%.• Growth in Ostomy Care was broad based with good contribution from recent product launches and led by Europe and Emerging Markets ex. China. ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.